CARsgen Therapeutics Updates Share Repurchase Plan and Sees Increased Stake from Key Shareholder

Tip Ranks
2025.11.13 10:08
portai
I'm PortAI, I can summarize articles.

CARsgen Therapeutics Holdings Ltd. has updated its share repurchase plan, allowing the buyback of up to 25,461,295 shares over the next 50 trading days, funded by non-IPO raised funds. This reflects the board's belief in the company's undervalued share price and long-term growth potential. Additionally, substantial shareholder YIJIE Biotech Holding Limited has increased its stake, indicating confidence in CARsgen's growth. The latest analyst rating for the stock is a Sell with a price target of HK$14.92.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has shared an announcement.

CARsgen Therapeutics Holdings Limited has announced an update to its share repurchase plan, allowing the company to buy back up to 25,461,295 shares in the open market over the next 50 trading days. This move, funded by non-IPO raised funds, reflects the board’s belief that the current share price undervalues the company’s business prospects and demonstrates confidence in its long-term growth. Additionally, YIJIE Biotech Holding Limited, a substantial shareholder, has increased its stake in the company, indicating strong confidence in CARsgen’s potential for growth and investment value.

The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.

More about CARsgen Therapeutics Holdings Ltd.

CARsgen Therapeutics Holdings Limited is a biotechnology company specializing in the development of innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. The company is focused on advancing its proprietary technologies and expanding its market presence in the global biopharmaceutical industry.

Average Trading Volume: 2,137,706

Technical Sentiment Signal: Hold

Current Market Cap: HK$9.94B

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.